CIP
LAB icon

Chartwell Investment Partners’s Standard BioTools LAB Stock Holding History

Chartwell Investment Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-98,631
Closed -$457K – 425
2019
Q3 		$457K Hold
98,631
– – 0.02% 391
2019
Q2 		$1.22M Buy
+98,631
New +$1.26M 0.04% 366

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Chartwell Investment Partners's LAB Position: Q4 2019 in Review

Chartwell Investment Partners sold out of Standard BioTools (LAB) in Q4 2019, closing a stake of 98,631 shares — an estimated $457K sold.

Chartwell Investment Partners first reported a position in LAB in Q2 2019 and held it in 2 quarters. The position peaked at $1.22M in Q2 2019. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

  • Chartwell Investment Partners reported no remaining Standard BioTools position as of Q4 2019 after selling out during the quarter.
  • Chartwell Investment Partners sold 98,631 Standard BioTools shares in Q4 2019, an estimated $457K.
  • Chartwell Investment Partners first reported a position in Standard BioTools in Q2 2019 and held it in 2 quarters.
  • Chartwell Investment Partners's Standard BioTools position peaked at $1.22M in Q2 2019.
  • 99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on Chartwell Investment Partners's 13F filing for Q4 2019, filed 29 Jan 2020.